Ginkgo Pharmaceutical (Suzhou) Co., Ltd.
PrivateLast Round
Series B
Jun 21, 2017
Total Funding Raised
$20M
Company Overview
Ginkgo Pharmaceutical (Suzhou) Co., Ltd. is a pharmaceutical company that specializes in the research, development, and commercialization of drugs for viral illnesses, including hepatitis C, hepatitis B, and influenza.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Ginkgo Pharmaceutical (Suzhou) Co., Ltd. Comparables
Compare Ginkgo Pharmaceutical (Suzhou) Co., Ltd. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Nanjing Zenshine Pharmaceuticals Co., Ltd. | 85% | |
| Beijing Kawin Technology Share-Holding Co., Ltd. | 78% | |
| Ascletis Pharma Inc. | 75% |
For institutional investors. Book with your work email.
Ginkgo Pharmaceutical (Suzhou) Co., Ltd. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Jun 21, 2017 | ||||
| Strategic | Apr 10, 2017 | ||||
| Series A | Oct 1, 2015 |
For institutional investors. Book with your work email.
Ginkgo Pharmaceutical (Suzhou) Co., Ltd. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Kaitai Capital | Series B |
| Shiyu Capital | Strategic |
| Lilly Asia Ventures | Series B, Series A |
| Cowin Capital | Series B |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 21, 2017
$20M round with participation from Cowin Capital and Lilly Asia Ventures.
- Apr 10, 2017
Raised a strategic round with Shiyu Capital participating.
For institutional investors. Book with your work email.
Ginkgo Pharmaceutical (Suzhou) Co., Ltd. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Ginkgo Pharmaceutical (Suzhou) Co., Ltd.'s valuation, stock price, and market status.
Is Ginkgo Pharmaceutical (Suzhou) Co., Ltd. a public or private company?
Ginkgo Pharmaceutical (Suzhou) Co., Ltd. is a private company.
What is the current stock price of Ginkgo Pharmaceutical (Suzhou) Co., Ltd.?
Ginkgo Pharmaceutical (Suzhou) Co., Ltd. is a private company, so its shares have no public market price. Caplight tracks Ginkgo Pharmaceutical (Suzhou) Co., Ltd.'s secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Ginkgo Pharmaceutical (Suzhou) Co., Ltd. worth (valuation)?
Valuation information for Ginkgo Pharmaceutical (Suzhou) Co., Ltd. is not publicly available.
Can I buy Ginkgo Pharmaceutical (Suzhou) Co., Ltd. stock?
Ginkgo Pharmaceutical (Suzhou) Co., Ltd. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Ginkgo Pharmaceutical (Suzhou) Co., Ltd.'s last funding round?
Ginkgo Pharmaceutical (Suzhou) Co., Ltd.'s most recent funding round was Series B on June 21, 2017.
Who are the main investors in Ginkgo Pharmaceutical (Suzhou) Co., Ltd.?
Key investors in Ginkgo Pharmaceutical (Suzhou) Co., Ltd. include Kaitai Capital, Shiyu Capital, Lilly Asia Ventures, Cowin Capital.
Will Ginkgo Pharmaceutical (Suzhou) Co., Ltd. IPO soon?
No public IPO plans have been announced for Ginkgo Pharmaceutical (Suzhou) Co., Ltd..
How can I track Ginkgo Pharmaceutical (Suzhou) Co., Ltd. secondary market activity?
Caplight tracks bids, offers, and trades in Ginkgo Pharmaceutical (Suzhou) Co., Ltd.'s shares on secondary markets.